eISSN: 1896-9151
ISSN: 1734-1922
Archives of Medical Science
Current issue Archive Manuscripts accepted About the journal Special issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
6/2015
vol. 11
 
Share:
Share:
more
 
 
abstract:
Basic research

CtBP2 Overexpression is associated with tumorigenesis and poor clinical outcome of prostate cancer

Changwen Zhang, Shuanghui Li, Baomin Qiao, Kuo Yang, Ranlu Liu, Baojie Ma, Yan Liu, Zhihong Zhang, Yong Xu

Arch Med Sci 2015; 11, 6: 1318–1323
Online publish date: 2015/12/11
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Introduction: The aim of the study was to evaluate the expression of CtBP2 in prostate cancer and to determine its relationship with clinicopathologic parameters.

Material and methods: The expression of CtBP2 in 119 prostate cancer tissues and 41 normal tissues was examined by qPCR and Western blot analysis, and the results were correlated with clinicopathologic parameters.

Results: CtBP2 expression in prostate cancer tissues was higher than that in normal samples. CtBP2 overexpression was closely correlated with serum prostatic specific antigen (PSA) (p = 0.018), advanced tumor stage (T3) (p = 0.025), higher Gleason scores (p = 0.019), positive extraprostatic extension (p = 0.012), positive vascular invasion (p = 0.011) and perineural invasion (p = 0.035). However, no significant association was found between CtBP2 abnormal expression and other parameters, including age (p = 0.776), positive lymph node (p = 0.872) and positive surgical margin (p = 0.37). Moreover, CtBP2 overexpression was significantly associated with poor clinical outcome of prostate cancer (p = 0.0168).

Conclusions: CtBP2 is overexpressed in prostate cancer, and its increased expression is closely associated with tumor progression and the outcome of prostate cancer.
keywords:

prostate cancer, CtBP2, clinicopathologic parameters

references:
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
Kawalec P, Paszulewicz A, Holko P, Pilc A. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. A systematic review and meta-analysis. Arch Med Sci 2012; 8: 765-75.
Subramanian T, La Regina M, Chinnadurai G. Enhanced ras oncogene mediated cell transformation and tumorigenesis by adenovirus 2 mutants lacking the C-terminal region of E1a protein. Oncogene 1989; 4: 415-20.
Bergman L, Blaydes J. C-terminal binding proteins: Emerging roles in cell survival and tumorigenesis. Apoptosis 2006; 11: 879-88.
Chinnadurai G. The transcriptional corepressor CtBP: a foe of multiple tumor suppressors. Cancer Res 2009; 69: 731-4.
Paliwal S, Kovi RC, Nath B, Chen YW, Lewis BC, Grossman SR. The alternative reading frame tumor suppressor antagonizes hypoxia-induced cancer cell migration via interaction with the COOH-terminal binding protein corepressor. Cancer Research 2007; 67: 9322-9.
Chen YW, Paliwal S, Draheim K, Grossman SR, Lewis BC. p19Arf Inhibits the invasion of hepatocellular carcinoma cells by binding to C-terminal binding protein. Cancer Res 2008; 68: 476-82.
Paliwal S, Pande S, Kovi RC, et al. Targeting of C-terminal binding protein (CtBP) by ARF results in p53-independent apoptosis. Mol Cell Biol 2006; 26: 2360-72.
Paliwal S, Pande S, Kovi RC, Sharpless NE, Bardeesy N, Grossman SR. Targeting of C-terminal binding protein (CtBP) by ARF results in p53-independent apoptosis. Mol Cell Biol 2006; 26: 2360-72.
Thomas G, Jacobs KB, Yeager M, et al. Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet 2008; 40: 310-5.
Heidenreich A, Varga Z, Von Knobloch R. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J Urol 2002; 167: 1681-6.
Aydemir H, Albayrak S, Canguven O, et al. Anorectal functions after perineal and retropubic radical prostatectomy – a prospective clinical and anal manometric assessment. Arch Med Sci 2011; 7: 138-42.
Zhang C, Zhang S, Zhang D, Zhang Z, Xu Y, Liu S. A lung cancer gene GPC5 could also be crucial in breast cancer. Mol Genet Metabol 2011; 103: 104-5.
Chinnadurai G. Transcriptional regulation by C-terminal binding proteins. Int J Biochem Cell Biol 2007; 39: 1593-607.
Bonazzi M, Spano S, Turacchio G, et al. CtBP3/BARS drives membrane fission in dynamin-independent transport pathways. Nat Cell Biol 2005; 7: 570-80.
Boyd JM, Subramanian T, Schaeper U, La Regina M, Bayley S, Chinnadurai G. A region in the C-terminus of adenovirus 2/5 E1a protein is required for association with a cellular phosphoprotein and important for the negative modulation of T24-ras mediated transformation, tumorigenesis and metastasis. EMBO J 1993; 12: 469-78.
Landmann C, Hunig R. Prostatc specific antigen as an indicator of response to radiotherapy in prostate cancer. Int J Radiat Oncol Biol Physics 1989; 17: 1073-6.
Antenor JAV, Roehl KA, Eggener SE, Kundu SD, Han M, Catalona WJ. Preoperative PSA and progression-free survival after radical prostatectomy for Stage T1c disease. Urology 2005; 66: 156-60.
Parlaktas BS, Atilgan D, Gencten Y, et al. A pilot study of the association of manganese superoxide dismutase and glutathione peroxidase 1 single gene polymorphisms with prostate cancer and serum prostate specific antigen levels. Arch Med Sci 2015; 11: 994-1000.
Bergman LM, Birts CN, Darley M, Gabrielli B, Blaydes JP. CtBPs Promote cell survival through the maintenance of mitotic fidelity. Mol Cell Biol 2009; 29: 4539-51.
Birts CN, Harding R, Soosaipillai G, et al. Expression of CtBP family protein isoforms in breast cancer and their role in chemoresistance. Biol Cell 2010; 103: 1-19.
Kovi RC, Paliwal S, Pande S, Grossman SR. An ARF/CtBP2 complex regulates BH3-only gene expression and p53-independent apoptosis. Cell Death Differ 2010; 17: 513-21.
FEATURED PRODUCTS
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe